ELDOQUIN FORTE 4% Price

Overview

Welcome to Dwaey, specifically on ELDOQUIN FORTE 4% Cream page.
This medicine contains an important and useful components, as it consists of Hydroquinone.
ELDOQUIN FORTE 4% is available in the market in concentration 40mg/g and in the form of Cream.

VALEANT PHARMACEUTICALS INTERNATIONAL is the producer of ELDOQUIN FORTE 4% and it is imported from USA, The most popular alternatives of ELDOQUIN FORTE 4% are listed downward .

Mode Of Action

Hydroquinone is a topical depigmentating agent used in hyperpigmentation conditions by suppressing melanocyte metabolic processes. It also increases melanin excretion from melanocytes and prevents its production.

Indication

• Chloasma
• Melasma
• Freckles
• Senile lentigines
• Hyperpigmentation

Precaution

Hydroquinone is a skin bleaching agent which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this medication.Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin to check in 24 hours. Minor redness is not a contraindication, but where there is itching or vesicle formation or excessive inflammatory response, further treatment is not advised. If no bleaching or lightening effect is noted after 2 months of treatment, the medication should be discontinued.Contact with the eyes and lips should be avoided. Hydroquinone should not be applied to cut or abraded skin. Lactation: unknown if distributed in breast milk; use caution

Side Effects

• Mild skin irritation and sensitization (burning
• stinging
• and allergic dermatitis) Dryness and fissuring of paranasal and infraorbital
• Ochronosis Colloid milium (after chronic use of up to 8 years)

Contra indication

Hydroquinone is contraindicated to patients with prior history of hypersensitivity or allergic reaction to hydroquinone or other ingredients in the preparation.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks